文献速递神经儿科影像MR

儿童及青年动静脉畸形患者接受费瑞莫司增强MRI后的脑铁评估:病例对照研究

Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study.
PubMed 文献 · Radiology · 2020-09-15

本回顾性病例对照研究纳入2014年1月至2018年1月接受至少一剂费瑞莫司的儿童及青年脑动静脉畸形患者,按年龄和性别匹配未暴露对照。在定量磁化率图和R2*图上测量深部灰质感兴趣区,组间及亚组内比较均未发现磁化率值和R2*值存在显著差异。

要点

  • 费瑞莫司暴露组与未暴露对照组深部灰质磁化率值差异无统计学意义(P=.21)。
  • 费瑞莫司暴露组与未暴露对照组深部灰质R2*值差异无统计学意义(P=.24)。
  • 亚组首次与末次MRI间深部灰质磁化率值(P=.95)和R2*值(P=.54)差异无统计学意义。

核心结论

  • 在儿童及青年动静脉畸形患者中,费瑞莫司暴露组与未暴露组间深部灰质磁化率值和R2*值未见总体显著差异,暴露者随访前后亦未见显著差异,未提示脑内铁潴留。

研究设计与样本

  • 回顾性病例对照研究,纳入2014年1月至2018年1月接受至少一剂费瑞莫司的儿童及青年脑动静脉畸形患者,按年龄和性别匹配未暴露对照。
  • 费瑞莫司暴露组17例(平均年龄±标准差,13岁±5;男性9例),对照组21例(平均年龄14岁±5;男性11例),亚组9例(平均年龄12岁±6;男性4例)。
  • 费瑞莫司平均给药次数2±1次(范围1至4次)。
  • 亚组首次与末次费瑞莫司给药平均间隔14个月±8(范围1至25个月)。
  • 在定量磁化率图和R2*图像上于深部灰质结构放置感兴趣区,记录平均磁化率值和R2*值。

关键影像表现/征象

  • 齿状核磁化率值病例组0.06 ppm±0.04 vs 对照组0.02 ppm±0.03,R2*值病例组23.87 sec-1±4.13 vs 对照组21.7 sec-1±5.26。
  • 黑质磁化率值病例组0.08 ppm±0.06 vs 对照组0.04 ppm±0.05,R2*值病例组27.46 sec-1±5.58 vs 对照组24.96 sec-1±5.3。
  • 苍白球磁化率值病例组0.14 ppm±0.05 vs 对照组0.08 ppm±0.07,R2*值病例组30.75 sec-1±5.14 vs 对照组28.82 sec-1±6.62。
  • 壳核磁化率值病例组0.03 ppm±0.02 vs 对照组0.02 ppm±0.02,R2*值病例组20.63 sec-1±2.44 vs 对照组19.65 sec-1±3.6。
  • 尾状核磁化率值病例组-0.1 ppm±0.04 vs 对照组-0.06 ppm±0.05,R2*值病例组18.21 sec-1±3.1 vs 对照组18.83 sec-1±3.32;丘脑磁化率值病例组0 ppm±0.03 vs 对照组0.02 ppm±0.02,R2*值病例组16.49 sec-1±3.6 vs 对照组18.38 sec-1±2.09。

诊断标准与关键数值

  • 组间比较磁化率值P=.21,R2*值P=.24,均未达统计学显著差异。
  • 亚组首次与末次MRI比较磁化率值P=.95,R2*值P=.54,均未达统计学显著差异。
  • 亚组齿状核首次MRI磁化率值0.06 ppm±0.05、R2*值25.78 sec-1±5.9,末次MRI磁化率值0.06 ppm±0.02、R2*值25.55 sec-1±4.71。
  • 亚组黑质首次MRI磁化率值0.06 ppm±0.06、R2*值28.26 sec-1±9.56,末次MRI磁化率值0.07 ppm±0.06、R2*值25.65 sec-1±6.37;苍白球首次MRI磁化率值0.13 ppm±0.07、R2*值27.53 sec-1±8.88,末次MRI磁化率值0.14 ppm±0.06、R2*值29.78 sec-1±6.54。
  • 亚组壳核首次MRI磁化率值0.03 ppm±0.03、R2*值19.78 sec-1±3.51,末次MRI磁化率值0.03 ppm±0.02、R2*值19.73 sec-1±3.01;尾状核首次MRI磁化率值-0.09 ppm±0.05、R2*值21.38 sec-1±4.72,末次MRI磁化率值-0.1 ppm±0.05、R2*值18.75 sec-1±2.68;丘脑首次MRI磁化率值0.01 ppm±0.02、R2*值17.65 sec-1±5.16,末次MRI磁化率值0 ppm±0.02、R2*值15.32 sec-1±2.49。

临床应用与阅片要点

  • 对于需多次接受费瑞莫司增强MRI的儿童及青年动静脉畸形患者,可在定量磁化率图和R2*图上测量深部灰质磁化率值和R2*值以评估脑铁沉积。
  • 本研究中费瑞莫司暴露组与未暴露组间及亚组暴露前后深部灰质磁化率值和R2*值均未见显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Iron oxide nanoparticles are an alternative contrast agent for MRI. Gadolinium deposition has raised safety concerns, but it is unknown whether ferumoxytol administration also deposits in the brain. Purpose To investigate whether there are signal intensity changes in the brain at multiecho gradient imaging following ferumoxytol exposure in children and young adults. Materials and Methods This retrospective case-control study included children and young adults, matched for age and sex, with brain arteriovenous malformations who received at least one dose of ferumoxytol from January 2014 to January 2018. In participants who underwent at least two brain MRI examinations (subgroup), the first and last available examinations were analyzed. Regions of interests were placed around deep gray structures on quantitative susceptibility mapping and R2* images. Mean susceptibility and R2* values of regions of interests were recorded. Measurements were assessed by linear regression analyses: a between-group comparison of ferumoxytol-exposed and unexposed participants and a within-group (subgroup) comparison before and after exposure. Results Seventeen participants (mean age ± standard deviation, 13 years ± 5; nine male) were in the ferumoxytol-exposed (case) group, 21 (mean age, 14 years ± 5; 11 male) were in the control group, and nine (mean age, 12 years ± 6; four male) were in the subgroup. The mean number of ferumoxytol administrations was 2 ± 1 (range, one to four). Mean susceptibility (in parts per million [ppm]) and R2* (in inverse seconds [sec-1]) values of the dentate (case participants: 0.06 ppm ± 0.04 and 23.87 sec-1 ± 4.13; control participants: 0.02 ppm ± 0.03 and 21.7 sec-1 ± 5.26), substantia nigrae (case participants: 0.08 ppm ± 0.06 and 27.46 sec-1 ± 5.58; control participants: 0.04 ppm ± 0.05 and 24.96 sec-1 ± 5.3), globus pallidi (case participants: 0.14 ppm ± 0.05 and 30.75 sec-1 ± 5.14; control participants: 0.08 ppm ± 0.07 and 28.82 sec-1 ± 6.62), putamina (case participants: 0.03 ppm ± 0.02 and 20.63 sec-1 ± 2.44; control participants: 0.02 ppm ± 0.02 and 19.65 sec-1 ± 3.6), caudate (case participants: -0.1 ppm ± 0.04 and 18.21 sec-1 ± 3.1; control participants: -0.06 ppm ± 0.05 and 18.83 sec-1 ± 3.32), and thalami (case participants: 0 ppm ± 0.03 and 16.49 sec-1 ± 3.6; control participants: 0.02 ppm ± 0.02 and 18.38 sec-1 ± 2.09) did not differ between groups (susceptibility, P = .21; R2*, P = .24). For the subgroup, the mean interval between the first and last ferumoxytol administration was 14 months ± 8 (range, 1-25 months). Mean susceptibility and R2* values of the dentate (first MRI: 0.06 ppm ± 0.05 and 25.78 sec-1 ± 5.9; last MRI: 0.06 ppm ± 0.02 and 25.55 sec-1 ± 4.71), substantia nigrae (first MRI: 0.06 ppm ± 0.06 and 28.26 sec-1 ± 9.56; last MRI: 0.07 ppm ± 0.06 and 25.65 sec-1 ± 6.37), globus pallidi (first MRI: 0.13 ppm ± 0.07 and 27.53 sec-1 ± 8.88; last MRI: 0.14 ppm ± 0.06 and 29.78 sec-1 ± 6.54), putamina (first MRI: 0.03 ppm ± 0.03 and 19.78 sec-1 ± 3.51; last MRI: 0.03 ppm ± 0.02 and 19.73 sec-1 ± 3.01), caudate (first MRI: -0.09 ppm ± 0.05 and 21.38 sec-1 ± 4.72; last MRI: -0.1 ppm ± 0.05 and 18.75 sec-1 ± 2.68), and thalami (first MRI: 0.01 ppm ± 0.02 and 17.65 sec-1 ± 5.16; last MRI: 0 ppm ± 0.02 and 15.32 sec-1 ± 2.49) did not differ between the first and last MRI examinations (susceptibility, P = .95; R2*, P = .54). Conclusion No overall significant differences were found in susceptibility and R2* values of deep gray structures to suggest retained iron in the brain between ferumoxytol-exposed and unexposed children and young adults with arteriovenous malformations and in those exposed to ferumoxytol over time. © RSNA, 2020.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Iv M, Ng NN, Nair S, et al. Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study. Radiology. 2020. PMID: 32930651. doi:10.1148/radiol.2020200378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。